CN1554355A - 必特螺旋霉素及其在抗感染性疾病中的应用 - Google Patents
必特螺旋霉素及其在抗感染性疾病中的应用 Download PDFInfo
- Publication number
- CN1554355A CN1554355A CNA2003101224209A CN200310122420A CN1554355A CN 1554355 A CN1554355 A CN 1554355A CN A2003101224209 A CNA2003101224209 A CN A2003101224209A CN 200310122420 A CN200310122420 A CN 200310122420A CN 1554355 A CN1554355 A CN 1554355A
- Authority
- CN
- China
- Prior art keywords
- spiramycin
- bitsoft
- iii
- pharmaceutical composition
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004187 Spiramycin Substances 0.000 title claims abstract description 89
- 229930191512 spiramycin Natural products 0.000 title claims abstract description 89
- 229960001294 spiramycin Drugs 0.000 title claims abstract description 89
- 235000019372 spiramycin Nutrition 0.000 title claims abstract description 89
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 title claims abstract 12
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- -1 isovaleryl spiramycin Chemical compound 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 229950003659 spiramycin iii Drugs 0.000 claims description 6
- HSZLKTCKAYXVBX-VPIGJTHDSA-N Spiramycin-III Natural products CCC(=O)O[C@@H]1CC(=O)O[C@H](C)CC=CC=C[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O[C@H]4C[C@@](C)(O)[C@@H](O)[C@H](C)O4)[C@@H]([C@H]3O)N(C)C)[C@H]1OC HSZLKTCKAYXVBX-VPIGJTHDSA-N 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- GIDHDUYAXIVIMN-JJORJHTQSA-N CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC Chemical compound CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC GIDHDUYAXIVIMN-JJORJHTQSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- VCZCNQGYDMIUGX-FLROPGNWSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7 Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@@H](O[C@H]2[C@@H]([C@H]([C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@](C)(O)C3)[C@@H](C)O2)N(C)C)O)[C@@H](CC=O)C[C@H]1C)OC)OC(=O)CC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 VCZCNQGYDMIUGX-FLROPGNWSA-N 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 238000012360 testing method Methods 0.000 abstract description 13
- 241000204031 Mycoplasma Species 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 206010035742 Pneumonitis Diseases 0.000 abstract 1
- ACTOXUHEUCPTEW-CEUOBAOPSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-CEUOBAOPSA-N 0.000 description 69
- 238000000576 coating method Methods 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012545 processing Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 description 6
- 241000193996 Streptococcus pyogenes Species 0.000 description 6
- 230000002725 anti-mycoplasma Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229950006796 spiramycin ii Drugs 0.000 description 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- ZPCCSZFPOXBNDL-LWXQEXJOSA-N Spiramycin-II Natural products CO[C@H]1[C@@H](CC(=O)O[C@H](C)CC=CC=C[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@@H](CC=O)[C@@H]1O[C@@H]3O[C@H](C)[C@@H](O[C@H]4C[C@@](C)(O)[C@@H](O)[C@H](C)O4)[C@@H]([C@H]3O)N(C)C)OC(=O)C ZPCCSZFPOXBNDL-LWXQEXJOSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- PNMQDIDLWTXQLZ-RZELCZIWSA-N CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O Chemical compound CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O PNMQDIDLWTXQLZ-RZELCZIWSA-N 0.000 description 4
- GCIQAGXAZPUQNA-YDPAJNKASA-N CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C GCIQAGXAZPUQNA-YDPAJNKASA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- UEWVJVSNLOFCHN-YTMXBESRSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7 Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](OC(C)=O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 UEWVJVSNLOFCHN-YTMXBESRSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000009495 sugar coating Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001217966 Streptomyces spiramyceticus Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- GIGQFSYNIXPBCE-UHFFFAOYSA-N alumane;platinum Chemical compound [AlH3].[Pt] GIGQFSYNIXPBCE-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ROUPZXDBSPQFLE-UHFFFAOYSA-N triazanium;phosphate;hydrate Chemical compound [NH4+].[NH4+].[NH4+].O.[O-]P([O-])([O-])=O ROUPZXDBSPQFLE-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Abstract
Description
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 平均 | |
isv-III | 34.86 | 36.22 | 33.84 | 37.03 | 34.19 | 37.76 | 35.37 | 39.79 | 36.13 |
isv-II | 24.67 | 24.93 | 24.36 | 24.85 | 20.02 | 25.85 | 25.19 | 24.18 | 24.27 |
isv-I | 13.79 | 14.89 | 13.42 | 14.02 | 15.86 | 15.34 | 13.33 | 12.38 | 14.13 |
Bu-IIIiBu-III | 3.56 | 3.45 | 3.54 | 3.56 | 3.22 | 3.16 | 3.04 | 2.62 | 3.27 |
Bu-IIiBu-II | 0.77 | 0.27 | 0.22 | 0.57 | 0.33 | 0.24 | 0.26 | 0.27 | 0.37 |
Pr-III | 5.11 | 5.48 | 5.70 | 5.23 | 6.73 | 4.76 | 5.13 | 5.32 | 5.43 |
Pr-II | 0.85 | 0.82 | 0.86 | 0.89 | 0.30 | 0.17 | 0.28 | 0.26 | 0.33 |
Ac-III | 8.13 | 5.74 | 7.43 | 7.16 | 7.43 | 5.68 | 7.37 | 7.36 | 7.04 |
Ac-II | 2.84 | 1.92 | 3.05 | 3.08 | 3.47 | 1.89 | 3.18 | 3.09 | 2.82 |
总isv | 73.32 | 76.04 | 71.62 | 75.9 | 70.07 | 78.95 | 73.89 | 76.35 | 74.53 |
总4”酰化 | 94.58 | 93.72 | 92.42 | 96.39 | 91.55 | 94.85 | 93.15 | 95.27 | 93.79 |
Mp | 实验次数 | 必特螺旋霉素 |
Mp-1 | 8 | 0.06-0.125 |
Mp-2 | 3 | 0.06 |
Mp-3 | 3 | 0.03-0.125 |
Mp-4 | 3 | 0.03-0.125 |
菌株 | MIC微克/ml |
肺炎链球菌31108 | 0.12 |
肺炎链球菌9757 | 0.25 |
肺炎链球菌9618 | 0.06 |
肺炎链球菌50 | 0.06 |
化脓性链球菌A12 | 0.5 |
化脓性链球菌3008 | 0.5 |
化脓性链球菌772 | 0.25 |
化脓性链球菌97129 | 0.25 |
金葡菌ATCC25923 | 1.00 |
金葡菌209p | 1.00 |
金葡菌15 | 0.5 |
金葡菌9776 | 1.00 |
表葡菌26069 | 1.00 |
表葡菌9760 | 0.5 |
表葡菌32 | 0.25 |
表葡菌9784 | 0.5 |
流感嗜血杆菌58530 | 0.06 |
流感嗜血杆菌11 | 0.25 |
组别(mg/kg) | 动物数(只) | 动物只数中Mp生长情况 |
- + + | ||
200 | 10 | 8 2 0 |
40 | 10 | 3 2 5 |
20 | 10 | 0 1 9 |
感染对照 | 10 | 1 1 8 |
感染菌 | 剂量mg/kg | 死亡率% | ED50mg/kg |
肺炎链球菌 | 22 | 10 | 11.72 |
17 | 30 | ||
12 | 50 | ||
7 | 80 | ||
化脓性链球菌 | 74 | 0 | 28.69 |
52 | 30 | ||
30 | 60 | ||
8 | 90 | ||
金葡菌 | 75 | 0 | 32.06 |
53 | 40 | ||
31 | 60 | ||
9 | 90 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310122420 CN1237976C (zh) | 2003-12-23 | 2003-12-23 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310122420 CN1237976C (zh) | 2003-12-23 | 2003-12-23 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1554355A true CN1554355A (zh) | 2004-12-15 |
CN1237976C CN1237976C (zh) | 2006-01-25 |
Family
ID=34338656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310122420 Expired - Lifetime CN1237976C (zh) | 2003-12-23 | 2003-12-23 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1237976C (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102060894A (zh) * | 2010-12-08 | 2011-05-18 | 华东理工大学 | 高速逆流色谱法制备异戊酰螺旋霉素ⅲ |
CN102229634A (zh) * | 2010-05-25 | 2011-11-02 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用 |
CN102247396A (zh) * | 2010-05-25 | 2011-11-23 | 沈阳同联集团有限公司 | 左旋可利霉素、其药物组合物、制备方法及应用 |
CN102260308A (zh) * | 2010-05-25 | 2011-11-30 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素iii、其制剂、制备方法及应用 |
WO2011147313A1 (zh) * | 2010-05-25 | 2011-12-01 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素i、ii或iii,及其制剂、制备方法及应用 |
CN102311471A (zh) * | 2010-05-25 | 2012-01-11 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素ii、其制剂、制备方法及应用 |
CN103142520A (zh) * | 2013-03-15 | 2013-06-12 | 沈阳同联集团有限公司 | 一种可利霉素片及其制备方法 |
CN105497053A (zh) * | 2015-12-31 | 2016-04-20 | 沈阳同联集团有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
WO2018184587A1 (zh) * | 2017-04-06 | 2018-10-11 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
WO2019141256A1 (zh) * | 2018-01-19 | 2019-07-25 | 沈阳福洋医药科技有限公司 | 可利霉素或其活性成分的用途 |
CN110051679A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种延缓衰老和/或延长寿命的组合物及其用途 |
CN110051678A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种预防和/或治疗糖尿病的药物及用途 |
CN110051680A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用 |
CN110384802A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
CN110384710A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
CN111939168A (zh) * | 2019-05-16 | 2020-11-17 | 沈阳福洋医药科技有限公司 | 一种用于预防、缓解和/或治疗纤维化的药物、组合产品及其应用 |
US10858659B2 (en) | 2015-12-31 | 2020-12-08 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Biosynthetic gene cluster of carrimycin |
RU2768583C2 (ru) * | 2018-01-19 | 2022-03-24 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Ингибитор мишени рапамицина в клетках млекопитающих, фармацевтическая композиция и их применение |
-
2003
- 2003-12-23 CN CN 200310122420 patent/CN1237976C/zh not_active Expired - Lifetime
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2647237C1 (ru) * | 2010-05-25 | 2018-03-14 | Шенянг Фуянг Фармасьютекал Технолоджи Ко.Лтд. | Левоизовалерилспирамицин iii, препараты, способ приготовления и употребления |
EP2578596A4 (en) * | 2010-05-25 | 2013-11-06 | Shenyang tonglian group co ltd | LEVOCARRIMYCIN, ITS PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF |
CN102247396A (zh) * | 2010-05-25 | 2011-11-23 | 沈阳同联集团有限公司 | 左旋可利霉素、其药物组合物、制备方法及应用 |
CN102260308A (zh) * | 2010-05-25 | 2011-11-30 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素iii、其制剂、制备方法及应用 |
EP3210990A1 (en) | 2010-05-25 | 2017-08-30 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Levoisovalerylspiramycin iii and preparations, preparation methods and uses thereof |
WO2011147316A1 (zh) * | 2010-05-25 | 2011-12-01 | 沈阳同联集团有限公司 | 左旋可利霉素、其药物组合物、制备方法及应用 |
CN102311471A (zh) * | 2010-05-25 | 2012-01-11 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素ii、其制剂、制备方法及应用 |
EP2578595A1 (en) * | 2010-05-25 | 2013-04-10 | Shenyang Tonglian Group Co., Ltd. | Levoisovalerylspiramycin i, ii or iii, preparations, preparation methods and uses thereof |
EP2578596A1 (en) * | 2010-05-25 | 2013-04-10 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
WO2011147313A1 (zh) * | 2010-05-25 | 2011-12-01 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素i、ii或iii,及其制剂、制备方法及应用 |
US20130150316A1 (en) * | 2010-05-25 | 2013-06-13 | Shenyang Toglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
JP2013528166A (ja) * | 2010-05-25 | 2013-07-08 | センヤン トンリァン グループ カンパニー,リミテッド | レボイソバレリルスピラマイシンi、ii又はiiiとその製剤、調製方法及び応用 |
JP2013528167A (ja) * | 2010-05-25 | 2013-07-08 | センヤン トンリァン グループ カンパニー,リミテッド | レボロキタマイシン、その薬物組成物、調製方法及び応用 |
CN102311471B (zh) * | 2010-05-25 | 2013-10-16 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素ii、其制剂、制备方法及应用 |
EP2578595A4 (en) * | 2010-05-25 | 2013-11-06 | Shenyang tonglian group co ltd | LEVOISOVALERYLSPIRAMYCIN I, II OR III, PREPARATES, MANUFACTURING METHOD AND USES THEREOF |
CN102229634A (zh) * | 2010-05-25 | 2011-11-02 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用 |
CN102229634B (zh) * | 2010-05-25 | 2014-05-28 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用 |
CN102260308B (zh) * | 2010-05-25 | 2014-05-28 | 沈阳同联集团有限公司 | 左旋异戊酰螺旋霉素iii、其制剂、制备方法及应用 |
US8778896B2 (en) | 2010-05-25 | 2014-07-15 | Shenyang Tonglian Group Co., Ltd. | Levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof |
US9089586B2 (en) * | 2010-05-25 | 2015-07-28 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
KR20160017124A (ko) * | 2010-05-25 | 2016-02-15 | 쉔양 통리엔 그룹 컴패니, 리미티드 | 레보이소발레릴스피라마이신 ii 또는 iii, 제제, 제조 방법 및 용도 |
KR20160019970A (ko) * | 2010-05-25 | 2016-02-22 | 쉔양 통리엔 그룹 컴패니, 리미티드 | 레보캐리마이신, 약학 조성물, 제조방법 및 응용 |
EP3210991A1 (en) | 2010-05-25 | 2017-08-30 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Levoisovalerylspiramycin ii and preparations, preparation methods and uses thereof |
RU2593499C2 (ru) * | 2010-05-25 | 2016-08-10 | Шенянг Тонглиан Груп Ко., Лтд. | Лекарственная форма левокарримицина, способ его получения и использования |
RU2593498C2 (ru) * | 2010-05-25 | 2016-08-10 | Шенянг Тонглиан Груп Ко., Лтд | Левовращающие изовалерил-спирамицины 1, ii, iii, их препараты, способ приготовления и употребление |
KR101706518B1 (ko) * | 2010-05-25 | 2017-02-14 | 쉔양 통리엔 그룹 컴패니, 리미티드 | 레보이소발레릴스피라마이신 ii 또는 iii, 제제, 제조 방법 및 용도 |
KR101706519B1 (ko) * | 2010-05-25 | 2017-02-14 | 쉔양 통리엔 그룹 컴패니, 리미티드 | 레보캐리마이신, 약학 조성물, 제조방법 및 응용 |
RU2647236C1 (ru) * | 2010-05-25 | 2018-03-14 | Шенянг Фуянг Фармасьютекал Технолоджи Ко. Лтд. | Левоизовалерилспирамицин ii, препараты, способ приготовления и употребления |
CN102060894A (zh) * | 2010-12-08 | 2011-05-18 | 华东理工大学 | 高速逆流色谱法制备异戊酰螺旋霉素ⅲ |
CN103142520A (zh) * | 2013-03-15 | 2013-06-12 | 沈阳同联集团有限公司 | 一种可利霉素片及其制备方法 |
CN105497053B (zh) * | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
RU2733382C2 (ru) * | 2015-12-31 | 2020-10-01 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Способ применения карримицина против резистентности инфекции, спровоцированной микобактерией туберкулеза |
WO2017114095A1 (zh) * | 2015-12-31 | 2017-07-06 | 沈阳同联集团有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
CN105497053A (zh) * | 2015-12-31 | 2016-04-20 | 沈阳同联集团有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
US11000708B2 (en) | 2015-12-31 | 2021-05-11 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin in Mycobacterium tuberculosis infection resistance |
US10858659B2 (en) | 2015-12-31 | 2020-12-08 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Biosynthetic gene cluster of carrimycin |
WO2018184587A1 (zh) * | 2017-04-06 | 2018-10-11 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
CN110545820B (zh) * | 2017-04-06 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
US11077126B2 (en) | 2017-04-06 | 2021-08-03 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor |
RU2746047C1 (ru) * | 2017-04-06 | 2021-04-06 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение карримицина и его фармацевтически приемлемой соли для производства медикаментов для лечения и/или профилактики опухоли |
CN110545820A (zh) * | 2017-04-06 | 2019-12-06 | 沈阳福洋医药科技有限公司 | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 |
JP2020516609A (ja) * | 2017-04-06 | 2020-06-11 | 沈陽福洋医薬科技有限公司Shenyang Fuyang Pharmaceutical Technology Co., Ltd | 腫瘍を治療および/または予防する薬物の調製におけるカリマイシンおよびその薬学的に許容可能な塩の応用 |
CN110051679B (zh) * | 2018-01-19 | 2022-02-22 | 沈阳福洋医药科技有限公司 | 一种延缓衰老和/或延长寿命的组合物及其用途 |
CN110051680B (zh) * | 2018-01-19 | 2022-02-18 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用 |
WO2019141256A1 (zh) * | 2018-01-19 | 2019-07-25 | 沈阳福洋医药科技有限公司 | 可利霉素或其活性成分的用途 |
JP7152052B2 (ja) | 2018-01-19 | 2022-10-12 | 沈陽福洋医薬科技有限公司 | カリマイシン又はその活性成分の用途 |
CN110051680A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用 |
JP2021517887A (ja) * | 2018-01-19 | 2021-07-29 | 沈陽福洋医薬科技有限公司Shenyang Fuyang Pharmaceutical Technology Co., Ltd | カリマイシン又はその活性成分の用途 |
CN110051678A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种预防和/或治疗糖尿病的药物及用途 |
US11413302B2 (en) | 2018-01-19 | 2022-08-16 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin or active ingredients thereof and use thereof |
CN110051678B (zh) * | 2018-01-19 | 2022-02-18 | 沈阳福洋医药科技有限公司 | 一种预防和/或治疗糖尿病的药物及用途 |
RU2771046C2 (ru) * | 2018-01-19 | 2022-04-25 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение карримицина или его активных ингредиентов |
CN110051679A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种延缓衰老和/或延长寿命的组合物及其用途 |
RU2768583C2 (ru) * | 2018-01-19 | 2022-03-24 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Ингибитор мишени рапамицина в клетках млекопитающих, фармацевтическая композиция и их применение |
CN110384802B (zh) * | 2018-04-17 | 2021-09-17 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
CN110384802A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
CN110384710A (zh) * | 2018-04-17 | 2019-10-29 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
CN110384710B (zh) * | 2018-04-17 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
CN111939168A (zh) * | 2019-05-16 | 2020-11-17 | 沈阳福洋医药科技有限公司 | 一种用于预防、缓解和/或治疗纤维化的药物、组合产品及其应用 |
CN111939168B (zh) * | 2019-05-16 | 2023-02-03 | 沈阳福洋医药科技有限公司 | 一种用于预防、缓解和/或治疗纤维化的药物、组合产品及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1237976C (zh) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1237976C (zh) | 必特螺旋霉素及其在抗感染性疾病中的应用 | |
CN1147472C (zh) | 具有组蛋白脱乙酰酶抑制剂活性的苯甲酰胺制剂 | |
CN1314396C (zh) | 左旋奥硝唑在制备抗厌氧菌感染药物的应用 | |
CN102247396B (zh) | 左旋可利霉素、其药物组合物、制备方法及应用 | |
CN103319479A (zh) | 大黄酸小檗碱离子对化合物、制备方法及应用 | |
CN1305469C (zh) | 左旋奥硝唑在制备抗寄生虫感染的药物中的应用 | |
CN106822119A (zh) | 一种利福霉素‑硝基咪唑偶联分子的新用途 | |
CN1943675A (zh) | 清热化痰、止咳平喘的藏药药物组合物及其制备方法 | |
CN1149220C (zh) | 溴代台勾霉素化合物 | |
CN101926840A (zh) | 一种紫锥菊的超微粉散剂及其制备方法和应用 | |
CN101580805A (zh) | 布雷菲德菌素a产生菌及发酵法生产布雷菲德菌素a | |
CN105311047B (zh) | 一种替米考星药物包合物及其制备和应用 | |
CN1118471C (zh) | 鞣料云实素的制备工艺 | |
CN110384802A (zh) | 一种用于预防和/或治疗发热的药物、组合产品及其应用 | |
CN111494402B (zh) | 一种兽用复合维生素的片剂及其制备方法 | |
CN1872852A (zh) | 小檗碱衍生物及其制备方法和其药物组合物与用途 | |
CN107484880A (zh) | 一种党参药渣生物饲料添加剂及其制备方法与应用 | |
CN105294813A (zh) | 一种化合物止泻木碱及其在制备抑菌药物方面的应用 | |
CN1813783A (zh) | 一种阿奇霉素微丸胶囊及其制备方法 | |
CN1679914A (zh) | 还原型谷胱甘肽和依布硒啉的组合药物 | |
CN1224390C (zh) | 含吡咯并喹啉醌的治疗和预防脂肪肝的药物组合物 | |
CN103724177B (zh) | 一种具有抗真菌活性的化合物及其制备方法与应用 | |
CN116730961B (zh) | 一种没药烷型倍半萜类化合物及其作为MptpB抑制剂的应用 | |
CN1919215A (zh) | 一种红曲制剂及其制备方法 | |
CN109420163B (zh) | 治疗呼吸道感染的药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BIOMEDICAL TECHNOLOGY INST., CHINESE ACADEMY OF MEDICAL SCIENCES BEIJING CAPITAL SCIENCE-TECHNOLOGY GROUP CORPORATION Effective date: 20120426 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120426 Address after: 110042 Liaoning Province, Shenyang City District East Shuncheng Street Yucai Lane No. 18 Patentee after: SHENYANG TONGLIAN GROUP Co.,Ltd. Address before: 110042 Liaoning Province, Shenyang City District East Shuncheng Street Yucai Lane No. 18 Co-patentee before: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES Patentee before: SHENYANG TONGLIAN GROUP Co.,Ltd. Co-patentee before: Beijing Shouke Group Co. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Bite spiramycin and its use in anti inflammatory disease Effective date of registration: 20130924 Granted publication date: 20060125 Pledgee: Bohai International Trust Ltd. Pledgor: SHENYANG TONGLIAN GROUP Co.,Ltd. Registration number: 2013210000002 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20151010 Granted publication date: 20060125 Pledgee: Bohai International Trust Ltd. Pledgor: SHENYANG TONGLIAN GROUP Co.,Ltd. Registration number: 2013210000002 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Bite spiramycin and its use in anti inflammatory disease Effective date of registration: 20151016 Granted publication date: 20060125 Pledgee: Shengjing bank Limited by Share Ltd Shenyang Zhenghao branch Pledgor: SHENYANG TONGLIAN GROUP Co.,Ltd. Registration number: 2015210000012 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060125 |